02 August 2018
Visiongain’ has launched a new pharma report Global Stem Cell Technologies and Applications Market 2018-2018: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications
Visiongain believes that the next ten years in the stem cell market will see many crucial breakthroughs, including: multiple approvals, particularly in the cardiovascular segment but increasingly also in the CNS segment; increased use and clinical validation of hESCs and iPSCs; and major changes in the drug development process, enabled by new stem cell-based assays.
The lead analyst of the report commented “Advances in related areas of regenerative medicine, such as tissue engineering, bioprinting and biomaterials, could interact with stem cell development to generate new opportunities to treat disease. Organ regeneration would be a high priority for companies in this area; tissue engineering of a thymus using stem cells is an example. 3D printing could be used to form scaffolds and tissues for orthopaedic conditions and wound healing.
New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market. Scalability is often cited as one of the major barriers in translating promising pre-clinical and clinical-stage results into a valid and commercially viable therapy.”
Leading companies featured in the report include Mesoblast, Pharmicell, NuVasive, Orthofix, MEDIPOST, Reliance Life Sciences, Gamida Cell, Neuralstrem, ReNeuron, Apceth, Novartis, TiGenix, Ocata Therapeutics, Athersys.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.
15 June 2021
Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.
14 June 2021
Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period.
04 June 2021
The rising frequency of bacterial and viral diseases coupled with increased focus on immunisation programmes are two main reasons that are expected to boost the global anti-infective vaccines market’s growth in the coming years.